the company sinovac in china and bututan research center in brazil worked together. this is an inactivated virus vaccine. this means the team took the sars-cov-2 virus and changed it to make it harmless. the patient's body learns to recognize the harmless virus and then it can recognize the harmful, wild virus too. the company got permission to start phase iii trials on july 3. this virus is called coronavac.